Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - glyceryl trinitrate, quantity: 0.4 mg/actuation - spray, solution - excipient ingredients: peppermint oil; ethanol; sodium lactate; (s)-lactic acid; fractionated coconut oil; purified water; glyceryl caprylate/caprate - the treatment of acute angina pectoris. as well as relieving the pain of an acute attack nitrolingual pumpspray may be used prophylactically five to ten minutes prior to engaging in activities which may precipitate an acute attack.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

imtrade australia pty ltd - sulfur - water dispersible granule - sulfur mineral-sulfur active 800.0 g/kg - mixed function pesticide

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethambutol hydrochloride, quantity: 400 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; povidone; titanium dioxide; hypromellose; magnesium stearate; ethylcellulose; polyethylene glycol monomethyl ether; purified talc; maize starch; propylene glycol - ethambutol gh is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. it has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculous meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculosis of the skin and tuberculous eye diseases. it should not be used as the sole antituberculosis drug, but should be used in conjunction with at least one other antituberculosis drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies.,in patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs ? ethambutol, isoniazid, rifampicin and streptomycin - for the first 2-4 months. for example:,? ethambutol plus isoniazid plus rifampicin; or ? ethambutol plus isoniazid plus streptomycin,then continuing with a two drug regimen such as,? ethambutol plus isoniazid; or ? ethambutol plus rifampicin.,in patients who have received previous antituberculosis therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment cases ethambutol gh should be combined with at least one of the second-line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculosis drugs used with ethambutol have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. alternating drug regimens have also been utilised..

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethambutol hydrochloride, quantity: 400 mg - tablet, film coated - excipient ingredients: purified talc; magnesium stearate; hypromellose; titanium dioxide; colloidal anhydrous silica; propylene glycol; ethylcellulose; polyethylene glycol monomethyl ether; maize starch; povidone - ethambutol gh is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. it has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculous meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculosis of the skin and tuberculous eye diseases. it should not be used as the sole antituberculosis drug, but should be used in conjunction with at least one other antituberculosis drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies.,in patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs ? ethambutol, isoniazid, rifampicin and streptomycin - for the first 2-4 months. for example:,? ethambutol plus isoniazid plus rifampicin; or ? ethambutol plus isoniazid plus streptomycin,then continuing with a two drug regimen such as,? ethambutol plus isoniazid; or ? ethambutol plus rifampicin.,in patients who have received previous antituberculosis therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment cases ethambutol gh should be combined with at least one of the second-line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculosis drugs used with ethambutol have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. alternating drug regimens have also been utilised.

Australia - English - Department of Health (Therapeutic Goods Administration)

biomarin pharmaceutical australia pty ltd - cerliponase alfa, quantity: 30 mg/ml - injection, solution - excipient ingredients: dibasic sodium phosphate heptahydrate; sodium chloride; potassium chloride; magnesium chloride hexahydrate; calcium chloride dihydrate; water for injections; monobasic sodium phosphate monohydrate - brineura is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (cln2) disease, also known as tripeptidyl peptidase 1 (tpp1) deficiency.

Australia - English - Department of Health (Therapeutic Goods Administration)

ambu australia pty ltd - 60963 - flexible video bronchoscope, single-use - intended to be used for the visualisation of the trachea, to assist the entry and positioning of an airway tube and percutaneous dilatational tracheostomy. images are relayed to the reusable ambu monitor.

Australia - English - Department of Health (Therapeutic Goods Administration)

ambu australia pty ltd - 44962 - laryngoscope, intubation, flexible, video - the ascope is videoscope used to visualise the placement of endotracheal tubes and percutaneous dilatational tracheostomy. the images are displayed on the ambu monitor. this device is single patient use

Australia - English - Department of Health (Therapeutic Goods Administration)

ambu australia pty ltd - 45129 - cervical spine collar, single-use - the ambu perfit collar is a one-piece rigid cervical spine immobilisation device designed to assist the rescuer with the maintenance of neutral alignment, prevention of lateral (side to side)sway and anterior-posterior (forward and backward) flexion and extension of the cervical spine during patient transport or movement

Australia - English - Department of Health (Therapeutic Goods Administration)

ambu australia pty ltd - 18034 - endoscopic video image processor - the abox 2 is intended to display imaging data from compatable ambu visualisation devices

Australia - English - Department of Health (Therapeutic Goods Administration)

ambu australia pty ltd - 60963 - flexible video bronchoscope, single-use - the ascope bronchoscope is for endoscopic procedures and examination within the airways and tracheobronchial tree. it provides visualization via a compatible ambu display unit.